Spots Global Cancer Trial Database for Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Official Title: Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma
Study ID: NCT01747642
Conditions
Study Description
Brief Summary: Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
Detailed Description: To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Farabi General Hospital, Dhaka, , Bangladesh
Contact Details
Name: Mamun A Mahtab, MD, FACG
Affiliation: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
